IL-18 and IL-7 Cytokine Therapy for Hematopoietic Stem Cell Expansion

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies lack effective solutions for rebuilding weakened immune systems, particularly in patients with leukopenia or lymphopenia, and for enhancing hematopoietic stem cell engraftment and proliferation.

Innovation Solution

The use of IL-18 alone or in combination with IL-7 to promote the expansion and differentiation of hematopoietic stem cells and progenitor cells, enhancing their numbers and engraftment in bone marrow, thereby addressing immune system weaknesses and lymphopoiesis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current therapies are used to rebuild weakened immune systems, then treatment is provided, but effective solutions are lacking for patients with leukopenia or lymphopenia and for enhancing hematopoietic stem cell engraftment and proliferation

Engineering Contradiction:

Improveeffectiveness of immune system rebuilding therapyVSAvoidapplicability to leukopenia and lymphopenia patients

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent combines IL-18 and IL-7 cytokines into a unified therapeutic regimen to achieve synergistic effects. This combination therapy addresses multiple aspects of immune system rebuilding simultaneously, providing both stem cell expansion and differentiation support, thereby resolving the limitation of current single-therapy approaches

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent modifies therapeutic parameters by introducing specific cytokine concentrations and administration protocols. By optimizing IL-18 and IL-7 dosing regimens, the therapy achieves enhanced hematopoietic stem cell proliferation and engraftment rates, making it effective for previously untreated conditions like leukopenia and lymphopenia

Inventive Principle:

Principle #35Parameter changes

2Productivity

If IL-18 and IL-7 combination therapy is used to expand hematopoietic stem cells, then cell yields and engraftment are significantly increased, but the complexity of the therapy increases

Engineering Contradiction:

Improvecell yield and engraftment rateVSAvoidtherapy protocol complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent employs preliminary expansion of hematopoietic stem cells ex vivo using IL-18 and IL-7 before transplantation. This preliminary action allows cells to be pre-enriched and activated, achieving high cell yields and improved engraftment rates while simplifying the overall clinical protocol by consolidating complex processes into a standardized pre-treatment step

Inventive Principle:

Principle #10Preliminary action

3Speed

If IL-18 is used to promote progenitor cell expansion, then proliferation is accelerated, but there is a risk of skewing thymocyte subsets

Engineering Contradiction:

Improveproliferation rateVSAvoidthymocyte subset distribution

Core Design Contradiction:

SpeedVSStability of the object's composition

Solution Approach 1:

The patent applies local quality control by using IL-18 and IL-7 in specific combinations at controlled concentrations during different stages of progenitor cell expansion. This localized application ensures accelerated proliferation in target cells while maintaining proper thymocyte subset differentiation, preventing skewing through stage-specific cytokine optimization

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS9950037B2Enhancing progenitor cell numbers

Publication Date: 2018.04.24 OKLAHOMA MEDICAL RES FOUND

AI summary

Therapies using IL-18 alone or in combination with IL-7 for rebuilding weakened immune systems by increasing progenitor cell yields from bone marrow stem cells and/or increasing stem cell engraftment in bone marrow.